促性腺激素释放激素拮抗剂方案比激动剂长方案获得更多可利用胚胎

doi:10.16352/j.issn.1001-6325.2022.03.005

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (3): 479-483.doi: 10.16352/j.issn.1001-6325.2022.03.005

促性腺激素释放激素拮抗剂方案比激动剂长方案获得更多可利用胚胎

赵善可, 傅瑶, 褚大鹏, 付磊, 韩烁, 白雪燕, 李媛, 周雯慧^*

首都医科大学附属北京朝阳医院生殖医学中心,北京 100020

收稿日期:2021-11-24 修回日期:2021-12-24 出版日期:2022-03-05 发布日期:2022-03-04
通讯作者: ^* wenhuizhbjcy@126.com

Gonadotropin releasing hormone antagonist protocol brings about more available embryos than agonist long protocol

ZHAO Shan-ke, FU Yao, CHU Da-peng, FU Lei, HAN Shuo, BAI Xue-yan, LI Yuan, ZHOU Wen-hui^*

Medical Center for Human Reproduction, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China

Received:2021-11-24 Revised:2021-12-24 Online:2022-03-05 Published:2022-03-04
Contact: ^* wenhuizhbjcy@126.com

摘要/Abstract

摘要： 目的分析促性腺激素释放激素(GnRH)拮抗剂方案与传统激动剂长方案,哪种方案能获得更好的胚胎。方法纳入自2016年1月至2019年12月首次在北京朝阳医院生殖中心进行促排卵的病例,其中传统长方案组1 095例,拮抗剂方案组1 511例,并对相应的指标进行回顾性比较分析,包括受精率、胚胎质量、妊娠结局等。结果拮抗剂方案组可利用胚胎率(29.94% vs 31.59%)、双原核(2PN)优质胚胎率(44.67% vs 46.86%)、每取卵周期可利用囊胚数/OPU(1±2 vs 1±2)及可利用囊胚率(25.62% vs 29.66%)均显著高于长方案组。结论与传统长方案相比,拮抗剂方案能给患者带来更多可利用胚胎,加之与长方案类似的妊娠结局以及较低的卵巢过度刺激(OHSS)风险,拮抗剂方案正逐渐成为临床控制性促排卵(卵巢刺激)(COS)方案的首选。

关键词: 促性腺激素释放激素, 激动剂长方案, 拮抗剂方案, 胚胎质量, 妊娠结局

Abstract: Objective To compare the effect on embryo quality from gonadotropin releasing hormone(GnRH) antagonist protocol and from GnRH agonist long protocol, so as to find which protocol works better on embryo quality. Methods A retrospective analysis was performed with a total of 1 095 long protocol cycles and 1 511 antagonist protocol cycles from January 2016 to December 2019. The corresponding fertilization, embryo quality, pregnancy outcomes of the two groups, agonist vs antagonist, were calculated and analyzed. Results Antagonist group displayed significantly higher available embryo rate (29.94% vs 31.59%), good-quality two-pronuclear(2PN) embryo rate (44.67% vs 46.86%), available blastocyst/OPU(ovum pick-up)(1±2 vs 1±2) and available blastocyst rate (25.62% vs 29.66%) than the long protocol group. Conclusions Antagonist protocol may bring about more available embryos than agonist protocol. Together with a similar pregnancy outcome with agonist protocol and its efficacy in reducing ovarian hyperstimulation syndrome(OHSS) risk, antagonist protocol is the first choice for clinical contralled ovarian stimulation(COS) protocol.

Key words: gonadotropin releasing hormone, agonist long protocol, antagonist protocol, embryo quality, pregnancy outcome

中图分类号:

R711.6

赵善可, 傅瑶, 褚大鹏, 付磊, 韩烁, 白雪燕, 李媛, 周雯慧. 促性腺激素释放激素拮抗剂方案比激动剂长方案获得更多可利用胚胎[J]. 基础医学与临床, 2022, 42(3): 479-483.

ZHAO Shan-ke, FU Yao, CHU Da-peng, FU Lei, HAN Shuo, BAI Xue-yan, LI Yuan, ZHOU Wen-hui. Gonadotropin releasing hormone antagonist protocol brings about more available embryos than agonist long protocol[J]. Basic & Clinical Medicine, 2022, 42(3): 479-483.

参考文献

[1]李岩, 刘明慧, 白雪燕. 体外受精——胚胎移植中促性腺激素激动剂长方案与拮抗剂方案促排卵效果及结局比较[J]. 现代医学与健康研究电子杂志, 2018, 2:11-13.
[2]李宣, 刘嘉茵, 陈文森, 等. 比较长方案与拮抗剂方案在正常反应人群中的应用[J]. 中华生殖与避孕杂志, 2018, 38:219-223.
[3]Sahin S, Selcuk S, Devranoglu B, et al. Comparison of long GnRH agonist versus GnRH antagonist protocol in poor responders[J]. Turk J Obstet Gynecol, 2014, 11:203-206.
[4]Trenkic M, Popovic J, Kopitovic V, et al. Flexible GnRH antagonist protocol vs. long GnRH agonist protocol in patients with polycystic ovary syndrome treated for IVF: comparison of clinical outcome and embryo quality[J]. Ginekol Pol, 2016, 87:265-270.
[5]Yu R, Jin H, Huang X, et al. Comparison of modified agonist, mild-stimulation and antagonist protocols for in vitro fertilization in patients with diminished ovarian reserve[J]. J Int Med Res, 2018, 46:2327-2337.
[6]Prapas Y, Petousis S, Dagklis T, et al. GnRH antagonist versus long GnRH agonist protocol in poor IVF res-ponders: a randomized clinical trial[J]. Eur J Obstet Gynecol Reprod Biol, 2013, 166:43-46.
[7]Akin H, Kumbasar S, Sik BA, et al. Comparison of GnRH antagonist and agonist mini-dose long protocols in infertile cases undergoing controlled ovarian hyperstimulation[J]. Clin Exp Obstet Gynecol, 2017, 44:116-121.
[8]任昀, 杨硕, 杨蕊, 等, 促性腺激素释放激素激动剂长方案与拮抗剂方案对体外受精治疗妊娠结局的影响[J]. 北京大学学报:医学版, 2013, 45:877-881.
[9]Liu M, Liu S, Li L, et al. LH levels may be used as an indicator for the time of antagonist administration in GnRH antagonist protocols-A proof-of-concept study[J]. Frontiers Endocrinol, 2019, 10:67.doi:10.103389/fendo.201900067.
[10]Alpha Scientists in Reproductive M and Embryology ESIGo, The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting[J]. Hum Reprod, 2011, 26:1270-1283.
[11]Atabekoglu C, Taskin EA, Musali N, et al. The relation of serum estradiol level on day of hCG administration with pregnancy rates and embryo grades in agonist and antagonist down-regulated IVF/ICSI cycles[J]. Fertil Steril, 2013, 100:S506.doi:org/10.1016/j.fertnstert.2013.07.322.
[12]Vengetesh PM, Ramachandran A, Kumar P. Choosing GnRH antagonist protocol shows improved oocyte and embryo quality, coherent with the perifollicular vascularity (PFV) in assisted reproductive techniques[J]. J Clin Diagn Res, 2015, 9:QC24-28.

促性腺激素释放激素拮抗剂方案比激动剂长方案获得更多可利用胚胎

Gonadotropin releasing hormone antagonist protocol brings about more available embryos than agonist long protocol

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 6

编辑推荐

Metrics

本文评价

[1]	李运龙, 李蕊, 张玉萍, 王瑞, 刘燕萍. 孕期锌缺乏及对妊娠结局的影响[J]. 基础医学与临床, 2024, 44(4): 422-427.
[2]	王瑞, 柒铭铭, 杨微涛, 黄健, 肖锦艳, 李一春, 王永红, 刘燕萍. 综合营养管理对妊娠期糖尿病患者的血糖及妊娠结局的影响[J]. 基础医学与临床, 2024, 44(4): 434-439.
[3]	张纬, 余益香, 王琳, 闻明. 新型冠状病毒疫苗接种对妊娠结局的影响[J]. 基础医学与临床, 2023, 43(5): 794-797.
[4]	王战勇, 徐静, 梁燕, 岳育红. 孕中期血清唐氏综合征筛查与不良妊娠结局关联[J]. 基础医学与临床, 2022, 42(6): 955-959.
[5]	赵子君, 马薇. Kisspeptin在青春发动时相中作用的研究进展[J]. 基础医学与临床, 2022, 42(10): 1601-1605.
[6]	巩转娣;魏锁成;韦敏. GnRH-A促进雌兔FSH与LH分泌及卵巢发育的作用[J]. 基础医学与临床, 2011, 31(1): 13-18.